- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Ibrutinib (mcl) – November 2017
Ibrutinib (MCL): Capsule 140 mg; Imbruvica®
Last updated
2 March 2018